"Forecast Enrollment Rate in Clinical Trials" Is Published by PhESi

Share Article

For the first time, it is possible to accurately forecast enrollment rate in clinical trials, and shorten enrollment cycle time through proactively designed actions.

Gross Site Enrollment Rate for a Disease Condition

Enrollment cycle times are manageable. Specific actions from different function teams can be taken to shorten enrollment cycle time

“Forecasting enrollment rate in clinical trial” a peer reviewed article by Gen Li, President of PhESi, is published in APPLIED CLINICAL TRIALS online, on January 21, 2015.

While shortening patient enrollment cycle time has been a perennial challenge for clinical development organizations around the world, our understanding of enrollment cycle time as a concept is very limited, or purely mistaken in many aspects. Not surprisingly, the industry has not been able to achieve quantifiable improvement after tremendous efforts over the past few decades.

For the first time, as this article revealed, enrollment rates, both at investigator site level, and at clinical trial level, can be expressed by simple mathematical formulas. With this breakthrough in our understanding of enrollment rate, a key driver of enrollment cycle time, it is now possible to materially improve planning of clinical trials, and shorten enrollment cycle time with actions that can make quantifiable impact.

Specifically, it is clear now that there is limitation (operational boundary) in clinical trial execution, regardless how much resource being put into it. On the other hand, enrollment cycle times are manageable. Specific actions from different function teams can be taken to shorten enrollment cycle time (site activation process, site performance, trial design, and etc.)

PhESi owns the largest clinical development database. Combined with proprietary methods protected by patents in investigator site enrollment performance and clinical trial feasibility analysis, PhESi is a leading force in providing innovative solutions in clinical trial planning and execution, and adds quantifiable value for its clients.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Gen Li
PhESi
+1 860-739-8666
Email >
PhESi

Visit website